Effects of Chronic Use of Doxazosin in Men With Benign Prostatic Hyperplasia
NCT ID: NCT00730418
Last Updated: 2010-08-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
25 participants
INTERVENTIONAL
2007-01-31
2010-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety and Efficacy of QD Versus BID Silodosin With Lower Urinary Tract Symptoms Suggestive of BPH
NCT01260129
Study of a α1A Adrenoceptor Selective Antagonist Silodosin to Treat Severe Benign Prostatic Hyperplasia(BPH)
NCT01259531
Efficacy and Safety of Silodosin on Nocturia for Patients With Benign Prostatic Hyperplasia
NCT02106182
Combination Treatment With Doxazosin Plus TolterodineSR 2 mg Versus 4mg in Men With an Overactive Bladder (OAB) and Benign Prostatic Hyperplasia (BPH)
NCT00922506
A New Drug for Benign Prostatic Hyperplasia (BPH) Compared With Placebo
NCT00224120
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* Real-time RT-PCR
* Radioligand receptor binding
* Western blot
* Immunohistochemistry
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
doxazosin 4mg
doxazosin 4mg group
Doxazosin
Treatment with doxazosin 4mg daily for 24 mos
doxazosin 8mg
doxazosin 8mg group
Doxazosin
Treatment with doxazosin 8mg daily for 24 mos
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Doxazosin
Treatment with doxazosin 4mg daily for 24 mos
Doxazosin
Treatment with doxazosin 8mg daily for 24 mos
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* International prostatic symptom score \>= 8
* Maximal flow rate \< 15mL/sec
* baseline PSA 2.5-10 ng/mL
* Pathologically proven BPH
* No medication history for BPH
* Able to give fully informed consent
Exclusion Criteria
* Previous surgery for BPH
* Urologic cancer history
* Urethral stricture
* baseline PSA \> 10ng/mL
* BP \< 90/70 mmHg
* Orthotopic hypotension with syncope
* Serum Cr \> 2.0 mg/dl, alanine aminotransferase \> 1.5 times of normal limit
* Bacterial prostatitis within 1 year
* Urinary tract infection(UTI) more than 2 times within 1 year
* Active UTI or prostate biopsy within 1 month
* Unable to void
* Ped use because of incontinence
* Hypersensitivity to alpha-blocker that include quinazoline
* Unstable angina, Myocardial infarction, or cerebrovascular accident within 6 months
* Neurogenic bladder dysfunction (ex. multiple sclerosis, Parkinson's disease, Spinal injury etc.)
* Psychiatric problem
* Alcohol abuse or other drug abuse history
* Severe comorbidities unable to perform long-term trial
* seems not to be appropriate to this study because of any other reasons
50 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Samsung Medical Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Samsung Medical Center
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Kru-Sung Lee, Ph.D., M.D.
Role: PRINCIPAL_INVESTIGATOR
Samsung Medical Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Samsung Medical Center
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2006-08-118
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.